BRIEF-Spectrum Pharmaceuticals and Onxeo announce Phase 1 trial results of Belinostat with CHOP
December 07, 2015 at 02:29 AM EST
* Reported on Sunday complete response in 67 pct of patients with peripheral T-cell lymphoma in combination of Belinostat (Beleodaq) and standard CHOP (Cyclophosphamide, Hydroxyl-doxorubicin; Vincristine, and Prednisone)
